논문번호 | 262 | ||
논문제목(영문) | A prospective, multicentre, randomised, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilised patients with acute myocardial infarction after percutaneous coronary intervention | ||
국내외구분 | 국외 | SCI여부 | SCI(E) |
연구책임자역할 | 공저자 | ||
주저자명 | Park MW, Kim CJ | ||
교신저자명 | Chang K | ||
공동저자명 | Kim MC, Choo EH, Hwang BH, Park CS, Kim HY, Yoo KD, Jeon DS, Jeong MH, Seung KB, Ahn Y | ||
게제년월일 | 2021-02-01 | ||
ISSN | 1774-024X | ||
Impact Factor | 3.993 | ||
학술지명 | EUROINTERVENTION | ||
서지사항 | 0집 / 16권 / 14호, 페이지(1170 - 1176) | ||
요약초록문 (Abstract) 입력 |
Aims: In patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI), the risk of ischaemic complications is highest in the early phase (during the first 30 days), while most bleeding events occur predominantly during the maintenance phase of treatment (after the first 30 days). Data on the de-escalation of dual antiplatelet therapy by switching from ticagrelor to clopidogrel in stabilised AMI patients are limited. The aim of this study is to investigate the efficacy and safety of switching from ticagrelor to clopidogrel in AMI patients with no adverse event during the first month after the index PCI with newer-generation DES. Methods and results: TALOS-AMI is a multicentre, randomised, open-label study enrolling 2,590 AMI patients with no adverse events during the first month after the index PCI. One month after the index PCI, eligible patients are randomly assigned either to 1) aspirin 100 mg plus clopidogrel 75 mg daily, or to 2) aspirin 100 mg plus ticagrelor 90 mg twice daily, in a 1:1 ratio. The primary endpoint is a composite of cardiovascular death, MI, stroke, and bleeding type 2, 3 or 5 according to the Bleeding Academic Research Consortium (BARC) criteria from 1 to 12 months after the index PCI. Conclusions: The TALOS-AMI trial is the first large-scale, multicentre, randomised study exploring the efficacy and safety of the de-escalation of antiplatelet therapy by switching from ticagrelor to clopidogrel in stabilised AMI patients undergoing PCI. |
||
파일 |
전라남도 장성군 남면 삼태리 산 109 나노바이오연구원 3층 306호 TEL : 061-392-6243 Fax: 061-392-6243
Copyright ⓒ 2014 Korea Cardiovascular Stent Research Institute. All right Reserved